EVAUX® products have been adopted for several years now by patients with cutaneous and mucosal adverse reactions caused by cancer treatments such as chemotherapy and radiation therapy.
In particular EVAUX® helps to improve the compliance of treatment whose cutaneous adverse reactions
are often painful and even debilitating.
During the last five years, EVAUX® products have undergone highly conclusive clinical tests conducted
on patients treated for cancer.
On 3 June 2017, the results of the clinical study of ENONAIL nail care for the prevention and treatment of damaged nails, were presented at ASCO (www.asco.org) in Chicago, the annual convention held by the American Society of Clinical Oncology, which is attended by professionals from across the globe.
The success of our products with patients is due to the relief they rapidly procure and their capacity to prevent the reappearance of adverse reactions, even during frequent therapy sessions.